SCHEMBL6708115

SCHEMBL6708115

N#Cc1cc(Cl)ccc1NC(=O)c1ccc(Cl)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
KCNQ3 O43525 5/20 0.54
KCNQ2 O43526 5/20 0.54
KCNE1 P15382 5/20 0.54
KCNQ1 P51787 5/20 0.54
MDM4 O15151 1/20 0.52
TP53 P04637 1/20 0.52
MDM2 Q00987 1/20 0.52
KDR P35968 1/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
S1PR3 Q99500 1/20 0.47
F10 P00742 1/20 0.47
EGFR P00533 1/20 0.46
MAPT P10636 3/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6709850 0.88 RAB9A (0.59) MEN1KMT2AL3MBTL1KCNQ3KCNQ2
SCHEMBL6707088 0.81 KMT2A (0.55) MEN1KMT2AL3MBTL1KCNQ3KCNQ2
SCHEMBL1235368 0.80 HDAC1 (0.60) MEN1KMT2AL3MBTL1KCNQ3KCNQ2
SCHEMBL13102688 0.80 KCNMA1 (0.60) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL6706201 0.77 RAB9A (0.73) KCNQ3KCNQ2KCNE1KCNQ1MDM4
SCHEMBL6833057 0.77 MEN1 (0.65) MEN1KMT2AL3MBTL1KCNQ3KCNQ2
SCHEMBL6708107 0.76 F10 (0.56) MEN1KMT2AL3MBTL1KCNQ3KCNQ2
SCHEMBL6708189 0.76 NPC1 (0.60) MEN1KMT2AKCNQ3KCNQ2KCNE1
SCHEMBL418777 0.74 GRIK1 (0.62) MEN1KMT2AL3MBTL1KDRRAB9A
SCHEMBL4293229 0.74 KDM4E (0.48) MEN1KMT2AL3MBTL1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794397-B2 ANTICARCINOGENIC AGENTS CYTOVIA, INC. 2004-09-21 US claimed
US-20020010185-A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-01-24 US claimed
US-20040235846-A1 Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents CYTOVIA, INC. 2004-11-25 US disclosed
US-6794397-B2 ANTICARCINOGENIC AGENTS CYTOVIA, INC. 2004-09-21 US disclosed
EP-1257536-A1 SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2002-11-20 EP disclosed
US-20020010185-A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-01-24 US disclosed
WO-2001055115-A1 SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010185-A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP3, BAD, CASP12 MEN1 3202/4885KMT2A 3048/4885L3MBTL1 2930/4885
US-20040235846-A1 Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents NAMPT, BAD, NNT MEN1 3283/4885KMT2A 3188/4885L3MBTL1 2296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.